Empower Advisory Group
VRTX icon

Empower Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Empower Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$244K Sell
546
-12
-2% -$5.6K ﹤0.01% 456
2025
Q4 		$253K Sell
558
-29
-5% -$12.5K ﹤0.01% 441
2025
Q3 		$230K Buy
587
+38
+7% +$15.9K ﹤0.01% 490
2025
Q2 		$244K Sell
549
-86
-14% -$39.6K ﹤0.01% 446
2025
Q1 		$308K Sell
635
-27
-4% -$12.6K ﹤0.01% 395
2024
Q4 		$267K Buy
662
+47
+8% +$21.8K ﹤0.01% 432
2024
Q3 		$286K Sell
615
-11
-2% -$5.28K ﹤0.01% 410
2024
Q2 		$293K Buy
626
+29
+5% +$12.6K ﹤0.01% 398
2024
Q1 		$250K Sell
597
-28
-4% -$11.8K ﹤0.01% 448
2023
Q4 		$254K Buy
625
+2
+0.3% +$739 ﹤0.01% 424
2023
Q3 		$217K Sell
623
-64
-9% -$22.4K ﹤0.01% 433
2023
Q2 		$242K Sell
687
-47
-6% -$15.8K ﹤0.01% 436
2023
Q1 		$232K Buy
+734
New +$220K ﹤0.01% 444

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Empower Advisory Group's VRTX Position: Q1 2026 in Review

Empower Advisory Group reduced its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q1 2026, selling an estimated $5.6K and leaving 546 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #456.

Empower Advisory Group first reported a position in VRTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $308K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Empower Advisory Group held 546 shares of Vertex Pharmaceuticals worth $244K as of Q1 2026.
  • Empower Advisory Group sold 12 Vertex Pharmaceuticals shares in Q1 2026, an estimated $5.6K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Empower Advisory Group's portfolio in Q1 2026, its #456 holding.
  • Empower Advisory Group first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Empower Advisory Group's Vertex Pharmaceuticals position peaked at $308K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Empower Advisory Group's 13F filing for Q1 2026, filed 14 May 2026.